Postnatal maximal weight loss, fluid administration, and outcomes in extremely preterm newborns

Objective Evaluate maximal weight loss (MWL) and total fluid administration (TFA) association in first week after birth with outcomes among extremely preterm (EP) newborns. Study design We performed a retrospective analysis of the Preterm Erythropoietin Neuroprotection Trial evaluating first-week MW...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of perinatology 2022-08, Vol.42 (8), p.1008-1016
Hauptverfasser: Valentine, Gregory C., Perez, Krystle M., Wood, Thomas R., Mayock, Dennis E., Comstock, Bryan A., Puia-Dumitrescu, Mihai, Heagerty, Patrick J., Juul, Sandra E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective Evaluate maximal weight loss (MWL) and total fluid administration (TFA) association in first week after birth with outcomes among extremely preterm (EP) newborns. Study design We performed a retrospective analysis of the Preterm Erythropoietin Neuroprotection Trial evaluating first-week MWL, TFA, and association with in-hospital outcomes. Results Among n  = 883 included EP neonates, n  = 842 survived ≥ 7 days and were included in outcome analyses. MWL between 5% to 15% was associated with decreased odds of necrotizing enterocolitis compared to MWL > 15% (OR 0.49, 95% CI 0.25–0.98). Average TFA > 150 mL/kg birthweight/day was associated with increased odds of necrotizing enterocolitis (OR 3.22, 95% CI 1.40–7.42) and patent ductus arteriosus requiring surgery (OR 2.14, 95% CI 1.10–4.15). Conclusion MWL between 5% to 15% is a potentially optimal window of MWL. Increasing average TFA in the first week is associated with adverse neonatal outcomes. Prospective studies evaluating MWL and TFA and relationship to outcomes in EP neonates are needed. Clinical trial registration This study is a secondary analysis of pre-existing data from the PENUT Trial Registration: NCT01378273, https://clinicaltrials.gov/ct2/show/NCT01378273 .
ISSN:0743-8346
1476-5543
DOI:10.1038/s41372-022-01369-7